Join me on a 7-day adventure exploring Alaska aboard the Norwegian Encore, starting from Seattle. This video highlights my ...

Seahawks head coach Mike Macdonald discusses the recent trade for wide receiver Rashid Shaheed, expressing excitement about the addition (0:04). Macdonald highlights Shaheed's speed and playmaking ...

Seahawks head coach Mike Macdonald praised linebacker Tyrice Knight in his locker room speech for stepping in to lead the team in tackles on Sunday night in spite of his tumultuous start to the season ...

The Seahawks defeated the Washington Commanders 38-14 on Sunday Night Football after the bye week. Listen to head coach Mike Macdonald as he addresses the team following the prime-time win. Seahawks ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent ...

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for ...

MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver ...

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to ...

- Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine ...